PDAC Diagnostics

Pancreatic cancer is the seventh leading cause of cancer deaths globally and the third in the U.S., with poor prognosis due to late-stage diagnosis in over 80% of cases. With a five-year survival rate of just 11% and a growing number of diagnoses occurring in younger adults aged 30–40, there is an urgent need for advanced early detection methods and molecular diagnostic markers to improve patient outcomes

Three tests under PDAC DIAGNOSTICS

1. Onco Detect Pro

Empowering Earlier Interventions.

Our flagship next generation early detection service combining liquid biopsy technologies, advanced biomarker panels and AI-enhanced technology for earlier and sharper cancer diagnosis providing reliable and non-invasive solutions for proactive cancer screening.

2. OMNI ALERT

Continuous Monitoring for High-Risk Populations

Omni Alert Advanced is a breakthrough early detection platform that integrates two or more omics (genomic, transcriptomic, and proteomic data) with continuous biomarker surveillance. By revealing the earliest molecular signals of tumor initiation, it empowers clinicians to act decisively—transforming outcomes for high-risk patients and combating aggressive cancers such as pancreatic cancer before they advance.

3. TUMOR TRACE

Precision Screening Made Accessible

Tumor Trace is a real-time, non-invasive cancer surveillance service that leverages next-generation sequencing to dynamically monitor circulating biomarkers—including ctDNA, exosomes, and microRNAs—for early detection of tumor development, providing fast, accurate insights to support timely clinical interventions in high-risk patients.